Created in 2006 (France), I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome own 2757 sister brands and 17478 competing brands. The I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome brand is owned by SANOFI, a company listed in Paris. The ISIN, the company's International Securities Identification Number, is FR0000120578. The sector of I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome is Drug Manufacturers.

I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome is a brand of SANOFI (SAN) News

International deposit : 2006 Business sector Drug Manufacturers

News from the brand I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome

All news Marketscreener Logo
SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome)

loader
Stock exchange: More information on SANOFI (I-RESPOND Evaluation of IRbESartan (with or without HCTZ) in imProving insulin sensitivity in hypertensive patients with metabOlic syNDrome) Marketscreener Logo